Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.79% is 33% above its 5-year average of -47.76%, near the high end of its 5-year range (-76.87%–-31.79%).
18.20% above its 12-month average of -38.86%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.29%.
RETURN ON ASSETS (ROA)
-31.79%
RETURN ON ASSETS (ROA) AVG TTM
-38.86%
RETURN ON ASSETS (ROA) AVG 3Y
-47.00%
RETURN ON ASSETS (ROA) AVG 5Y
-47.76%
RETURN ON ASSETS (ROA) AVG 10Y
-46.80%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.20%
CURRENT VS 3Y AVG
+32.37%
CURRENT VS 5Y AVG
+33.44%
CURRENT VS 10Y AVG
+32.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-13.35%
vs the sector median at left
Definium Therapeutics, Inc.
Market Cap
$4.73B
Return on Assets (ROA)
-31.79%
TTM Avg
-38.86%
3Y Avg
-47.00%
5Y Avg
-47.76%
Market Cap
$4.69B
Return on Assets (ROA)
2.32%
TTM Avg
-1.14%
3Y Avg
-5.25%
5Y Avg
-6.57%
Market Cap
$4.66B
Return on Assets (ROA)
-9.97%
TTM Avg
-20.59%
3Y Avg
-24.65%
5Y Avg
-22.36%
Market Cap
$4.80B
Return on Assets (ROA)
-2.47%
TTM Avg
-26.65%
3Y Avg
-27.96%
5Y Avg
-27.52%
Market Cap
$4.86B
Return on Assets (ROA)
-82.32%
TTM Avg
-7.94%
3Y Avg
-19.90%
5Y Avg
-25.16%
Market Cap
$4.99B
Return on Assets (ROA)
4.59%
TTM Avg
-6.29%
3Y Avg
-18.57%
5Y Avg
-18.57%
Market Cap
$4.99B
Return on Assets (ROA)
-66.02%
TTM Avg
-31.80%
3Y Avg
-35.60%
5Y Avg
-41.38%
Market Cap
$4.44B
Return on Assets (ROA)
28.79%
TTM Avg
8.79%
3Y Avg
1.95%
5Y Avg
1.56%
Market Cap
$4.43B
Return on Assets (ROA)
-34.36%
TTM Avg
-56.86%
3Y Avg
-55.14%
5Y Avg
-55.14%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.73B | -31.79% | -38.86% | -47.00% | -47.76% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 2.32% | -1.14% | -5.25% | -6.57% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.66B | -9.97% | -20.59% | -24.65% | -22.36% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.80B | -2.47% | -26.65% | -27.96% | -27.52% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.86B | -82.32% | -7.94% | -19.90% | -25.16% |
| BillionToOne, Inc. (BLLN)vs › | $4.99B | 4.59% | -6.29% | -18.57% | -18.57% |
| Erasca, Inc. (ERAS)vs › | $4.99B | -66.02% | -31.80% | -35.60% | -41.38% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | 28.79% | 8.79% | 1.95% | 1.56% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | -34.36% | -56.86% | -55.14% | -55.14% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.33B | -41.11% | -28.92% | -26.43% | -22.29% |
ROA
-31.8%
ROE
-38.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -41.76% |
| 2024-12-31 | -35.97% |
| 2023-12-31 | -76.87% |
| 2022-12-31 | -33.41% |
| 2021-12-31 | -56.73% |
| 2020-12-31 | -41.83% |
| 2019-08-31 | -37.99% |
| 2018-08-31 | -24.28% |
| 2017-08-31 | -30.46% |
| 2016-08-31 | -88.73% |
| 2015-08-31 | -31.77% |
